<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531647</url>
  </required_header>
  <id_info>
    <org_study_id>NP28088</org_study_id>
    <nct_id>NCT01531647</nct_id>
  </id_info>
  <brief_title>A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers</brief_title>
  <official_title>A Study to Evaluate the Potential Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir When Given With Raltegravir in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, multiple dose, single sequence crossover study will evaluate the drug-drug
      interaction between danoprevir/low-dose ritonavir and raltegravir in healthy volunteers.
      Subjects will receive raltegravir on Days 1-4 and, after a washout period of 3 days,
      danoprevir and low-dose ritonavir on Days 8-21, in combination with raltegravir on Days
      18-21.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of steady-state ritonavir-boosted danoprevir on steady-state raltegravir pharmacokinetics: Area under the concentration-time curve (AUC)</measure>
    <time_frame>approximately 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of steady-state raltegravir on danoprevir/ritonavir pharmacokinetics: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose Days 8. 14, 15, 16 and 20, pre-and up to 24 h post-dose Days 17 and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Period 1 Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2 danoprevir/ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir</intervention_name>
    <description>100 mg q12h Days 8-21</description>
    <arm_group_label>Period 2 danoprevir/ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>400 mg q12h Days 1-4 and 18-21</description>
    <arm_group_label>Period 1 Control</arm_group_label>
    <arm_group_label>Period 2 danoprevir/ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>100 mg q12h Days 8-21</description>
    <arm_group_label>Period 2 danoprevir/ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy non-smoking male and female adults, 18 - 55 years of age, inclusive

          -  Healthy status defined by absence of evidence of any active or chronic disease

          -  Medical history without major, recent, or ongoing pathology

          -  Weight &gt;/= 50.0 kg

          -  Body mass index (BMI) 18.0 - 32-0 kg/m2

          -  Willingness to abstain from alcohol, xanthine-containing beverages or food (e.g.
             coffee, tea, cola, chocolate, &quot;energy drinks&quot;) from 48 hours prior to entry in the
             clinical site until discharge

          -  Females of child-bearing potential and males and their female partners of
             child-bearing potential must agree to use 2 forms of contraception, one of which must
             be a barrier method, during the study and for 90 days after the last drug
             administration. Acceptable barrier forms of contraception are condom and diaphragm;
             acceptable non-barrier forms of contraception for this study are non-hormonal
             intrauterine device (IUD) and/or spermicide

        Exclusion Criteria:

          -  Pregnant or lactating females or males with female partners who are pregnant or
             lactating

          -  Any history of clinically significant cardiovascular or cerebrovascular disease,
             hypertension, and/or infections

          -  Positive test for drugs of abuse at screening or prior to admission to the clinical
             site during any study period

          -  Positive for hepatitis B, hepatitis C or HIV infection

          -  Current smokers or subjects who have discontinued smoking less than 6 months prior to
             first dose of study medication

          -  Use of hormonal contraceptives within 30 days before the first dose of study
             medication

          -  History of clinically significant drug-related allergy (such as anaphylaxis) or
             hepatotoxicity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

